Re­gen­eron con­tin­ues reign atop the Covid treat­ment field with ex­pand­ed EUA for low­er dose sub­cu­ta­neous ver­sion of mAb cock­tail

The FDA on Fri­day au­tho­rized a new, low­er-dose ver­sion of Re­gen­eron’s Covid-19 mon­o­clon­al an­ti­body cock­tail for those with Covid-19 who are at high-risk of pro­gress­ing to hos­pi­tal­iza­tion.

The new dose is half the orig­i­nal­ly au­tho­rized dose, but the eas­i­er-to-ad­min­is­ter sub­cu­ta­neous ver­sion may not be the game-chang­er that ex­perts once en­vi­sioned. Re­gen­eron said in a state­ment that the com­bo “should be ad­min­is­tered by in­tra­venous (IV) in­fu­sion” and sub­cu­ta­neous in­jec­tions “are an al­ter­na­tive when IV in­fu­sion is not fea­si­ble and would lead to a de­lay in treat­ment.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER